

Resource Summary Report

Generated by [dkNET](#) on Sep 7, 2026

Brilliant Violet 785(TM) anti-mouse CD4

RRID:AB_2563053

Type: Antibody

Proper Citation

BioLegend Cat# 100552, RRID:AB_2563053

Antibody Information

URL: http://antibodyregistry.org/AB_2563053

Proper Citation: BioLegend Cat# 100552, RRID:AB_2563053

Target Antigen: CD4

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 785(TM) anti-mouse CD4

Description: This monoclonal targets CD4

Target Organism: mouse

Clone ID: Clone RM4-5

Antibody ID: AB_2563053

Vendor: BioLegend

Catalog Number: 100552

Alternative Catalog Numbers: 100551

Record Creation Time: 20231110T035218+0000

Record Last Update: 20260829T231807+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 785(TM) anti-mouse CD4.

No alerts have been found for Brilliant Violet 785(TM) anti-mouse CD4.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 42 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Sawada K, et al. (2026) Ambient temperature regulates CD4+ T cell tonic T cell receptor signaling and responsiveness. *iScience*, 29(5), 115801.

Li X, et al. (2026) The TCR-SUB1-DOCK2 axis promotes autoimmunity by driving pathogenic CD4+ T cell tissue infiltration. *Immunity*, 59(1), 98.

Maltez VI, et al. (2026) Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the tumor microenvironment. *Immunity*, 59(4), 1058.

Kudo-Saito C, et al. (2026) ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer. *Cancer research communications*, 6(2), 350.

Lee D, et al. (2026) Interleukin-4-producing type 2 innate lymphoid cells in the lymph node promote proallergic Tfh13 cell differentiation. *Immunity*, 59(7), 1860.

Huang H, et al. (2025) Biomimetic nanoimmunotherapy boosts spatiotemporal PANoptosis and reshapes desmoplastic tumor microenvironment. *Cell reports. Medicine*, 6(9), 102312.

Köhne M, et al. (2025) Satb1 directs the differentiation of TH17 cells through suppression of IL-2 expression. *Cell reports*, 44(7), 115866.

Hao Y, et al. (2025) Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition. *Cancer immunology research*, 13(2), 185.

Wu Z, et al. (2025) Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy. *Cell*.

Yeat NY, et al. (2025) Bro1 proteins determine tumor immune evasion and metastasis by controlling secretion or degradation of multivesicular bodies. *Developmental cell*, 60(15), 2114.

Huang L, et al. (2025) Interferon-driven CAF reprogramming augments immunogenic response to neoadjuvant radiotherapy in colorectal cancer. *Cell reports. Medicine*, 6(8), 102251.

Murphy MK, et al. (2025) The transcriptional repressor BLIMP1 enforces TCF-1-dependent and -independent restriction of the memory fate of CD8+ T cells. *Immunity*, 58(10), 2472.

Wientjens C, et al. (2025) Tolerance to ferroptosis facilitates lipid metabolism and pathogenic type 2 immunity in allergic airway inflammation. *Immunity*.

Wang S, et al. (2024) Disruption of MerTK increases the efficacy of checkpoint inhibitor by enhancing ferroptosis and immune response in hepatocellular carcinoma. *Cell reports. Medicine*, 5(2), 101415.

DuCote TJ, et al. (2024) EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas. *Cancer research communications*, 4(2), 388.

Textor J, et al. (2023) Machine learning analysis of the T cell receptor repertoire identifies sequence features of self-reactivity. *Cell systems*, 14(12), 1059.

Zhao B, et al. (2023) *Helicobacter* spp. are prevalent in wild mice and protect from lethal *Citrobacter rodentium* infection in the absence of adaptive immunity. *Cell reports*, 42(6), 112549.

Pan C, et al. (2023) Hepatocyte CHRNA4 mediates the MASH-promotive effects of immune cell-produced acetylcholine and smoking exposure in mice and humans. *Cell metabolism*, 35(12), 2231.

Duan J, et al. (2023) Characterizing CD4 T cell differentiation in mouse small intestine using T cell transfer, lamina propria preparation, and flow cytometry. *STAR protocols*, 4(3), 102485.

McClory SE, et al. (2023) The pseudokinase Trib1 regulates the transition of exhausted T cells to a KLR+ CD8+ effector state, and its deletion improves checkpoint blockade. *Cell reports*, 42(8), 112905.